Tag: report

The North America plywood market is projected to grow from US$ 16.82 billion in 2024 to US$ 23.37 billion by 2033, exhibiting a CAGR of 3.72%. This expansion is driven by increased government spending, technological advancements, and the demand for eco-friendly building materials. Green certifications and production innovations further boost market share. Significant infrastructural investments and urbanization stimulate plywood usage in residential and commercial sectors. Despite challenges such as volatile raw material prices and trade tariffs, key players like Boise Cascade and Weyerhaeuser Company continue to lead. The U.S., Canada, and Mexico are primary markets, each facing unique growth opportunities and challenges.

SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025, all dates inclusive (the “Class Period”), have until August 12, 2025 to seek appointment as lead plaintiff of the Tempus AI class action lawsuit. Captioned Shouse v. Tempus AI, Inc., No. 25-cv-06534 (N.D. Ill.), the Tempus AI class action lawsuit charges Tempus AI as well as certain of Tempus AI’s top executives with violations of the Securities Exchange Act of 1934.

Philippines' tobacco market declines in 2024 as smoking prevalence drops. Higher cigarette taxes raise retail prices, deterring consumption amid economic challenges. Economy brands thrive. The report provides insights into market size, trends, and forecasts to 2029. Explore key dynamics, major players, and strategic factors.

Q Assist the context aware agentic AI solution highlighted as innovative Gen AI Application in Financial Crime and Compliance

OSE Immunotherapeutics provides an update on ongoing proceedings

NEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the pricing of an underwritten public offering of 2,482,692 shares of its common stock at a price to the public of $19.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,363,469 shares of its common stock at a price to the public of $19.4999, which represents the per share public offering price for the shares of common stock less $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds to ArriVent from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $75 million. In addition, ArriVent has granted the underwriters a 30-day option to purchase up to an additional 576,923 shares of its common stock on the same terms and conditions. All of the securities are being offered by ArriVent.